# Additional file 1: Typical Monitoring Schedule

|  | Baseline Visit | Week 2 | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | While on injectable | Until end of treatment | End of treatment | Post-treatmentmonth 6 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Vital signs | X |  | X | X | X | X | X | X | Monthly |  |  |
| Performance status  | X |  |  | X |  |  |  |  |  |  | X |  |
| Brief peripheral neuropathy screen | X |  | X | X | X | X | X | X | Monthly | X | X |
| Audiometry | X |  | X | X | X | X | X | X | Monthly |  | X |  |
| Visual acuity and colorblindness screen | X |  | X | X | X | X | X | X | Monthly | X | X |
| Clinical assessment  | X | X | X | X | X | X | X | X | At all visits | X | X |
| Weight  | X | X | X | X | X | X | X | X | Monthly | X |  |
| Smear | X |  | X | X | X | X | X | X | Monthly | X | X |
| Culture | X |  | X | X | X | X | X | X | Monthly | X | X |
| First- and second-line DST | X |  |  |  |  |  |  |  |  |  |  |  |
| DST to new TB drugs |  |  |  |  |  |  |  | If culture-positive |
| Electrocardiogram | X | X | X | X | X | X | X | X |  |  | X | X |
| Full blood count, AST, ALT | X | X | X | X | X | X | X | X | Monthly | X |  |
| Urea, creatinine, serum potassium  | X |  | X | X | X | X | X | X | Monthly |  | X |  |
| TSH | X |  |  |  | X |  |  |  | Every 3 months |  |  |
| HBsAg, HCVAb, HbA1c | X |  |  |  |  |  |  |  |  |  |  |  |
| Pregnancy test | X |  |  |  |  |  |  |  |  |  |  |  |
| HIV serostatus, CD4, Viral load | X |  |  |  |  |  |  |  |  |  |  |  |
| Chest X-Ray | X |  |  |  |  |  |  | X |  |  | X |  |